Related Experiment Video

Updated: Apr 16, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.3K

[Effect and mechanism of fluorofenidone on organ fibrosis]

Hong Ma1, Zhangzhe Peng, Gaoyun Hu

  • 1Department of Nephrology, Xiangya Hospital, Changsha 410008, China.

Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences
|March 15, 2015
PubMed

Insights

Fluorofenidone shows promise as a new anti-fibrotic drug. This compound combats fibrosis by reducing inflammation, oxidation, and cell death, offering hope for treating fibrotic diseases.

Area of Science:

  • Fibrosis research
  • Pharmacology
  • Drug discovery

Background:

  • Fibrosis is a significant health concern across multiple organs.
  • Effective antifibrotic drugs for prevention are currently lacking.
  • Progressive fibrotic diseases pose a substantial clinical challenge.

Purpose of the Study:

  • To evaluate the therapeutic potential of fluorofenidone for fibrotic diseases.
  • To investigate the mechanisms underlying fluorofenidone's anti-fibrotic effects.
  • To explore fluorofenidone's applicability in treating renal, hepatic, and pulmonary fibrosis.

Main Methods:

  • Review of recent studies on fluorofenidone's pharmacological activities.
  • Analysis of fluorofenidone's effects on myofibroblast activation and proliferation.
  • Examination of fluorofenidone's impact on extracellular matrix degradation and cellular signaling.

Main Results:

  • Fluorofenidone exhibits multifunctional properties including anti-inflammatory, antioxidative, and anti-apoptotic effects.
  • The drug inhibits myofibroblast activation and proliferation.
  • Fluorofenidone promotes extracellular matrix degradation and modulates cellular signaling pathways.

Conclusions:

  • Fluorofenidone is a promising candidate for the prevention and treatment of fibrotic conditions.
  • Its multifaceted mechanism of action offers a novel therapeutic strategy.
  • Fluorofenidone demonstrates potential for attenuating renal, hepatic, and pulmonary fibrosis progression.

More Related Videos

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

1.9K
Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis07:08

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis

Published on: August 31, 2022

2.1K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
358
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K